{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:30:20Z","timestamp":1789421420822,"version":"build-2803163510"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2012,7,12]],"date-time":"2012-07-12T00:00:00Z","timestamp":1342051200000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Latent myeloproliferative disorders (MPDs) can be identified by Janus kinase 2 (JAK2) mutations in patients with idiopathic Budd-Chiari syndrome (BCS). The incidence and clinical outcomes of JAK2 mutations, novel ten-eleven translocation 2 (TET2) mutations, and the 46\/1 haplotype in BCS are unknown for liver transplantation (LT). We undertook molecular studies of 66 patients presenting with BCS and correlated the results with the clinical outcomes. An overt MPD was present in 20% of the cases, and a latent MPD confirmed by the presence of a JAK2 mutation was detected in 45%. Testing for a TET2 mutation identified MPDs at the molecular level in another 7% of the subset of patients with BCS who were evaluated. The 46\/1 haplotype frequency was significantly greater in BCS patients versus the general population (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). The presence of JAK2 and TET2 mutations had no impact on 1-year survival. Thirty-six patients underwent LT, and 12 developed liver-related thrombotic complications (33%). Ten of these 12 patients required retransplantation. Retransplantation was more likely in those patients who developed liver-related thrombotic complications (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). A JAK2 mutation was highly associated with the development of thrombotic complications after LT (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.005). In conclusion, the presence of JAK2V617F predicts hepatic and extrahepatic thrombotic complications after LT. Testing for TET2 mutations can identify another 7% of idiopathic BCS patients with molecular MPDs. Liver Transpl, 2012. \u00a9 2012 AASLD.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/lt.23443","type":"journal-article","created":{"date-parts":[[2012,4,3]],"date-time":"2012-04-03T09:03:46Z","timestamp":1333443826000},"page":"819-827","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":34,"title":["Prevalence and clinical outcomes of the 46\/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in budd-chiari syndrome and their impact on thrombotic complications post Liver Transplantation"],"prefix":"10.1097","volume":"18","author":[{"given":"Rachel H.","family":"Westbrook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C.","family":"Lea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azim M.","family":"Mohamedali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Orr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara N.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel D.","family":"Heaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.","family":"Wendon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"O'Grady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Heneghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam J.","family":"Mufti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20250124","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0025-6196(12)62109-0","article-title":"Classification of hepatic venous outflow obstruction: ambiguous terminology of the BuddChiari syndrome.","volume":"65","author":"Ludwig","year":"1990","journal-title":"Mayo Clin Proc"},{"key":"R2-11-20250124","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1056\/NEJMra020282","article-title":"The BuddChiari syndrome.","volume":"350","author":"Menon","year":"2004","journal-title":"N Engl J Med"},{"key":"R3-11-20250124","first-page":"981","article-title":"In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosispossible evidence of an occult myeloproliferative state.","volume":"76","author":"Pagliuca","year":"1990","journal-title":"Q J Med"},{"key":"R4-11-20250124","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-103-3-329","article-title":"Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with BuddChiari syndrome.","volume":"103","author":"Valla","year":"1985","journal-title":"Ann Intern Med"},{"key":"R5-11-20250124","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/0016-5085(88)90567-7","article-title":"Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders.","volume":"94","author":"Valla","year":"1988","journal-title":"Gastroenterology"},{"key":"R6-11-20250124","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-2007-996117","article-title":"Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with BuddChiari syndrome or portal vein thrombosis.","volume":"23","author":"De Stefano","year":"1997","journal-title":"Semin Thromb Hemost"},{"key":"R7-11-20250124","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"R8-11-20250124","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"R9-11-20250124","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gainoffunction mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"R10-11-20250124","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1053\/j.gastro.2006.04.008","article-title":"Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the BuddChiari syndrome.","volume":"130","author":"Patel","year":"2006","journal-title":"Gastroenterology"},{"key":"RU12-11-20250124","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"R13-11-20250124","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2141.2006.06348.x","article-title":"Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.","volume":"135","author":"Lasho","year":"2006","journal-title":"Br J Haematol"},{"key":"R14-11-20250124","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1038\/leu.2008.233","article-title":"Genetic complexity of myeloproliferative neoplasms.","volume":"22","author":"Kralovics","year":"2008","journal-title":"Leukemia"},{"key":"R15-11-20250124","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood-2005-12-4852","article-title":"Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders.","volume":"108","author":"BellanneChantelot","year":"2006","journal-title":"Blood"},{"key":"R16-11-20250124","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2008-03-143602","article-title":"Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 firstdegree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.","volume":"112","author":"Landgren","year":"2008","journal-title":"Blood"},{"key":"R17-11-20250124","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1182\/blood-2008-05-160739","article-title":"Disease anticipation in familial myeloproliferative neoplasms.","volume":"112","author":"Rumi","year":"2008","journal-title":"Blood"},{"key":"R18-11-20250124","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.","volume":"41","author":"Jones","year":"2009","journal-title":"Nat Genet"},{"key":"R19-11-20250124","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ng.341","article-title":"A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.","volume":"41","author":"Olcaydu","year":"2009","journal-title":"Nat Genet"},{"key":"R20-11-20250124","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.342","article-title":"A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)positive myeloproliferative neoplasms.","volume":"41","author":"Kilpivaara","year":"2009","journal-title":"Nat Genet"},{"key":"R21-11-20250124","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/leu.2009.59","article-title":"Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDSMPN and AML.","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"R22-11-20250124","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"R23-11-20250124","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/ng.391","article-title":"Acquired mutations in TET2 are common in myelodysplastic syndromes.","volume":"41","author":"Langemeijer","year":"2009","journal-title":"Nat Genet"},{"key":"R24-11-20250124","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers.","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"key":"R25-11-20250124","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/hep.21354","article-title":"Aiming at minimal invasiveness as a therapeutic strategy for BuddChiari syndrome.","volume":"44","author":"Plessier","year":"2006","journal-title":"Hepatology"},{"key":"R26-11-20250124","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0016-5085(75)80090-4","article-title":"The BuddChiari syndrome: correlation between hepatic scintigraphy and the clinical, radiological, and pathological findings in nineteen cases of hepatic venous outflow obstruction.","volume":"68","author":"Tavill","year":"1975","journal-title":"Gastroenterology"},{"key":"R27-11-20250124","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00000658-199001000-00007","article-title":"Liver transplantation for the BuddChiari syndrome.","volume":"211","author":"Halff","year":"1990","journal-title":"Ann Surg"},{"key":"R28-11-20250124","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/hep.1840210518","article-title":"Which is the best surgery for BuddChiari syndrome: venous decompression or liver transplantation? A singlecenter experience with 50 patients.","volume":"21","author":"Ringe","year":"1995","journal-title":"Hepatology"},{"key":"R29-11-20250124","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/gut.2005.071423","article-title":"Favourable medium term outcome following hepatic vein recanalisation andor transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome.","volume":"55","author":"Eapen","year":"2006","journal-title":"Gut"},{"key":"R30-11-20250124","doi-asserted-by":"crossref","first-page":"5","DOI":"10.12659\/AOT.882630","article-title":"Results of liver transplantation in the treatment of BuddChiari syndrome.","volume":"17","author":"Mackiewicz","year":"2012","journal-title":"Ann Transplant"},{"key":"R31-11-20250124","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/TP.0b013e3182247b05","article-title":"Longterm followup of liver transplantation for BuddChiari syndrome with antithrombotic therapy based on the etiology.","volume":"92","author":"Chinnakotla","year":"2011","journal-title":"Transplantation"},{"key":"R32-11-20250124","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jhep.2005.12.002","article-title":"Liver transplantation for BuddChiari syndrome: a European study on 248 patients from 51 centres.","volume":"44","author":"Mentha","year":"2006","journal-title":"J Hepatol"},{"key":"R33-11-20250124","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000224333","article-title":"Identification of MPL W515LK mutations in patients with primary myelofibrosis and essential thrombocythaemia by allelespecific polymerase chain reaction.","volume":"121","author":"Daly","year":"2009","journal-title":"Acta Haematol"},{"key":"R34-11-20250124","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood-2007-03-079673","article-title":"Prevalence and prognostic significance of allelic imbalance by singlenucleotide polymorphism analysis in lowrisk myelodysplastic syndromes.","volume":"110","author":"Mohamedali","year":"2007","journal-title":"Blood"},{"key":"R35-11-20250124","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1182\/blood-2010-03-274704","article-title":"Nextgeneration sequencing of the TET2 gene in 355 MDS and CMML patients reveals lowabundance mutant clones with early origins, but indicates no definite prognostic value.","volume":"116","author":"Smith","year":"2010","journal-title":"Blood"},{"key":"R36-11-20250124","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1200\/JCO.2009.22.6985","article-title":"Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome.","volume":"27","author":"Mohamedali","year":"2009","journal-title":"J Clin Oncol"},{"key":"R37-11-20250124","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1097\/00007890-200210270-00006","article-title":"Hematologic aspects of liver transplantation for BuddChiari syndrome with special reference to myeloproliferative disorders.","volume":"74","author":"Melear","year":"2002","journal-title":"Transplantation"},{"key":"R38-11-20250124","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/TP.0b013e3182247b05","article-title":"Longterm followup of liver transplantation for BuddChiari syndrome with antithrombotic therapy based on the etiology.","volume":"92","author":"Chinnakotla","year":"2011","journal-title":"Transplantation"},{"key":"RU40-11-20250124","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/hep.22192","article-title":"Thrombosis and anticoagulation in liver disease.","volume":"47","author":"Valla","year":"2008","journal-title":"Hepatology"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.23443","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.23443","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-201207000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T12:17:44Z","timestamp":1737721064000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-201207000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.23443","relation":{},"ISSN":["1527-6465"],"issn-type":[{"value":"1527-6465","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}